[go: up one dir, main page]

AR054336A1 - Tratamiento de enfermedades dermatologicas y del prurito - Google Patents

Tratamiento de enfermedades dermatologicas y del prurito

Info

Publication number
AR054336A1
AR054336A1 ARP060101247A ARP060101247A AR054336A1 AR 054336 A1 AR054336 A1 AR 054336A1 AR P060101247 A ARP060101247 A AR P060101247A AR P060101247 A ARP060101247 A AR P060101247A AR 054336 A1 AR054336 A1 AR 054336A1
Authority
AR
Argentina
Prior art keywords
treatment
dermatological
diseases
tyrosine kinase
prurite
Prior art date
Application number
ARP060101247A
Other languages
English (en)
Inventor
Morten Sloth Weidnerr
Original Assignee
Astion Dev As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Dev As filed Critical Astion Dev As
Publication of AR054336A1 publication Critical patent/AR054336A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Principio para el tratamiento de enfermedades dermatologicas, que comprende inhibir varios pasos cruciales de la cascada inflamatoria, incluyendo por lo menos la inhibicion de la proteína tirosina quinasa SYK, la proteína tirosina quinasa ZAP-70 y la fosfodiesterasa IV (PDE-IV) mediante la administracion por vía sistémica o topica en la piel de una cantidad eficaz de oxaprozina o de un compuesto estrechamente relacionado. La presente es particularmente util para el tratamiento de eczemas, tales como dermatitis de contacto y dermatitis atopica, y para el tratamiento del prurito. La presente también suministra composiciones dermatologicas para usar en el tratamiento de una enfermedad dermatologica.
ARP060101247A 2005-03-30 2006-03-30 Tratamiento de enfermedades dermatologicas y del prurito AR054336A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500437 2005-03-30
DKPA200500438 2005-03-30
DKPA200500949 2005-06-27
DKPA200500948 2005-06-27

Publications (1)

Publication Number Publication Date
AR054336A1 true AR054336A1 (es) 2007-06-20

Family

ID=38218953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101247A AR054336A1 (es) 2005-03-30 2006-03-30 Tratamiento de enfermedades dermatologicas y del prurito

Country Status (5)

Country Link
US (3) US20060251689A1 (es)
AR (1) AR054336A1 (es)
PE (1) PE20061303A1 (es)
TW (1) TW200722087A (es)
UY (1) UY29449A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
KR101456815B1 (ko) * 2005-02-16 2014-10-31 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
CN106008583A (zh) 2005-12-30 2016-10-12 安纳考尔医药公司 含硼的小分子
PL1988779T3 (pl) * 2006-02-16 2015-10-30 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
US20080107743A1 (en) * 2006-11-02 2008-05-08 Akpharma Inc. Composition and method for enhancing skin cell growth, proliferation and repair
EP3162787A1 (en) * 2007-03-20 2017-05-03 Evolva, Inc. Compositions comprising 5-epi-beta-vetivone, and its use as a fragrance
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CA2866527C (en) * 2007-10-10 2018-07-03 Bryan B. Fuller Use of isoeugenol esters in treating hyperpigmentation
US9616006B2 (en) 2007-10-10 2017-04-11 DermaMedics, LLC Methods and compositions for treating dermatological diseases and conditions
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
JP5745279B2 (ja) * 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
DE102008006393A1 (de) * 2008-01-28 2009-07-30 Beiersdorf Ag Verwendung von Lipidkomponenten gegen Pollenallergien
EP2187893A4 (en) * 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
AU2009221793B2 (en) 2008-03-06 2015-02-19 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
CA2744231A1 (en) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
JP2012520267A (ja) * 2009-03-13 2012-09-06 デベヴェ・テクノロジーズ 湿疹を処置する方法
AU2010281439A1 (en) * 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011022337A1 (en) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060196A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
CA2789276A1 (en) 2010-02-09 2011-08-18 Drexel University New signaling molecule involved in ultraviolet damage to skin
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
IT1406067B1 (it) * 2010-07-14 2014-02-06 Torino Politecnico Composizioni eudermiche.
WO2012033858A2 (en) 2010-09-07 2012-03-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2017007668A1 (en) * 2015-07-08 2017-01-12 Elliptical Therapeutics, Llc Improved topical ketoprofen formulations
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
EP3315488A1 (en) * 2016-10-28 2018-05-02 Elé Corporation Amino acid based amphoteric surfactant
WO2018201131A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
KR20200025244A (ko) * 2018-08-29 2020-03-10 연세대학교 산학협력단 푸니칼라진을 포함하는 소양증 예방, 개선 또는 치료용 조성물
KR20220124753A (ko) * 2020-01-08 2022-09-14 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카보닐]-4,4-디메틸펜트-2-엔니트릴을 포함하는 국소 약제학적 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32084B1 (en) * 1967-06-07 1973-04-04 Wyeth John & Brother Ltd Thiazole derivatives
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
US4190584A (en) * 1976-08-13 1980-02-26 John Wyeth & Brother Limited Process for preparing oxazoles
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
US4659728A (en) * 1985-02-25 1987-04-21 American Home Products Corporation Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid
US4773023A (en) * 1985-04-12 1988-09-20 Giardina Joseph J Apparatus for measuring the rate of heat dissipation
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
JPS63309077A (ja) * 1987-06-11 1988-12-16 Seikosha Co Ltd ビデオプリンタ
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2058975C (en) * 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US6017900A (en) * 1991-07-03 2000-01-25 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and nsaids
JPH07500113A (ja) * 1991-10-16 1995-01-05 リチャードソン、ビックス、インコーポレーテッド 薬物の改善された局所送達用の高皮膚浸透系
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
EP0652774B1 (en) * 1992-07-28 1997-05-07 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
EP0689100B1 (en) * 1994-06-22 2000-10-11 Canon Kabushiki Kaisha Carrier for electrophotography, two component type developer, and image forming method
US5948416A (en) * 1995-06-29 1999-09-07 The Procter & Gamble Company Stable topical compositions
EP0901372B1 (en) * 1996-05-20 2005-07-20 G.D. Searle LLC. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
CN1180709A (zh) * 1996-10-21 1998-05-06 湖南医科大学 遗传多发性外生骨疣家族的新多核苷酸和多肽基因
FR2765338B1 (fr) * 1997-06-25 1999-07-23 Inst Francais Du Petrole Dispositif de prelevement et/ou d'injection d'un echantillon de fluide permettant de conserver l'equilibre chimique et/ou thermodynamique
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
US5984416A (en) * 1998-04-30 1999-11-16 Calvin College Adjustable armrest
US6096896A (en) * 1998-10-15 2000-08-01 Farchemia S.R.L. Process for the preparation of 4.5-diphenyloxazole-2-propanoic acid
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6284802B1 (en) * 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
AP2003002922A0 (en) * 2001-05-31 2003-12-31 Pharmacia Corp Skin-permeable selective cyclooxygenase-2 inhibitor composition.
EP1426059A4 (en) * 2001-09-14 2007-01-17 Ono Pharmaceutical Co DRUGS FOR TREATING PRURIT
US20030211163A1 (en) * 2002-01-10 2003-11-13 Chong Kong Teck Combination antiviral therapy
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US20040186182A1 (en) * 2002-12-18 2004-09-23 Algorx Administration of capsaicinoids
AU2003297397A1 (en) * 2002-12-19 2004-07-14 Pharmacia Corp Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
CN1798568B (zh) * 2003-04-04 2011-05-11 尤尼根制药公司 用于哺乳动物皮肤护理的双重环氧合酶(cox)以及脂氧合酶(lox)抑制剂的组合物
US6852713B2 (en) * 2003-04-16 2005-02-08 Adolor Corporation Lactam derivatives and methods of their use

Also Published As

Publication number Publication date
TW200722087A (en) 2007-06-16
PE20061303A1 (es) 2006-12-07
US20060229347A1 (en) 2006-10-12
UY29449A1 (es) 2006-10-02
US20060222671A1 (en) 2006-10-05
US20060251689A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
AR054336A1 (es) Tratamiento de enfermedades dermatologicas y del prurito
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
TN2015000158A1 (en) New indanyloxydihydrobenzofuranylacetic acids
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
WO2011080568A8 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
MD20140082A2 (ro) Inhibitor al kinazei inductoare de apoptoză
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
PH12013501750A1 (en) Guanidine compound
PH12013502695A1 (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
ECSP10010192A (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios
EP2257161A4 (en) AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
WO2007053844A8 (en) Compositions and methods for treating inflammatory disorders

Legal Events

Date Code Title Description
FB Suspension of granting procedure